RNA-interference (RNAi) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The RNA-interference (RNAi) market is segmented by Application and Geography

Market Snapshot

rnai technology market
Study Period:

2018 - 2026

Base Year:

2020

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

10.12 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The RNA-interference (RNAi) market is expected to witness a CAGR of 10.12% during the forecast period. Certain factors that are driving the market growth include the increasing number of applications in molecular diagnostics, particularly in cancer and improving synthetic delivery carriers and chemical modifications to RNA.

Cancer diagnosis and treatment is currently undergoing a shift with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. For diagnostic purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized. The commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research. Thus, increasing the application of RNAi in molecular diagnosis and its viability as a therapeutic technique is expected to drive the growth of the RNAi market during the forecast period.

However, in recent years, there has been a decline in FDA drug approval rates. Getting FDA approval for a new drug has become extremely challenging. It approved less than half the number of new drugs in 2016 (19 so far) when compared to 2015 (45 total) and 2014 (41 total). Hence, despite the large investments, there has been a decline in the number of innovative drugs manufactured. FDA explains manufacturing standards and other complying issues as the major reasons for this declining trend. This can impede the growth of the RNAi therapeutics, especially since the miRNAs and siRNAs fall into the relatively new field of genetic medicine, wherein they may require more intensified clinical trials. The highly extensive clinical trials effectively result in low approval rates of drugs. This would mean that the stringent guidelines will be a major restraint for the growth of the market.

Scope of the Report

RNA interference is a biological process in which the RNA molecules are observed to inhibit gene expression or translation, by neutralizing the targeted mRNA molecules. Earlier, RNAi was identified by other names, such as co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The extensive study of each of these apparently different processes clarified that the identity of these phenomena were all in fact RNAi.

Application
Drug Discovery and Development
Therapeutics
Oncology
Ocular Disorders
Respiratory Disorders
Hepatitis B and C
Autoimmune Hepatitis
Neurological Disorders
Other Therapeutics
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oncology is Expected to Hold Significant Market Share in the Therapeutics Type

According to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. The number of new cases is expected to rise by about 70% over the next two decades.

Recent advancements, such as the development of small interfering RNA (siRNA) tolerant to nucleases and the development of non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this obstacle and facilitate the clinical use of RNAi-based therapeutics in the treatment of cancer.

Substantial pipeline for cancer therapies by companies and institutes such as Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. are expected to drive the market. In addition, many companies have invested in R&D for nanocarriers to deliver oligonucleotides for cancer treatment, which is expected to contribute to the oncology verticle.

trend 1

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do the Same in the Forecast Period

The U.S. has a number of RNAi therapeutics that are in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected growth in revenue that this market can have over the forecast period. For instance, AstraZeneca’s agreement with Ionis pharmaceuticals is one of the big deals that are investing heavily into RNA-interference technology

RNA-interference (RNAi) Market.png

To understand geography trends, Download Sample Report

Competitive Landscape

The RNA-interference (RNAi) market is highly competitive and consists of a few major players. Companies like Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics, among others, hold a substantial market share in the RNA-interference (RNAi) market.

Various developments have recently been taking place in the market, such as in November 2017, Arcturus Therapeutics merged with Alcobra Ltd. In October 2017, Alnylam and Vir formed a strategic alliance to advance RNAi therapeutics for infectious diseases.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Number of Applications in Molecular Diagnostics, Particularly in Cancer

      2. 4.2.2 Improving Synthetic Delivery Carriers and Chemical Modifications to RNA

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent FDA Regulations and Changing Reimbursement Environment

      2. 4.3.2 Unstable Potentially Immunogenic Nature of RNA

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Application

      1. 5.1.1 Drug Discovery and Development

      2. 5.1.2 Therapeutics

        1. 5.1.2.1 Oncology

        2. 5.1.2.2 Ocular Disorders

        3. 5.1.2.3 Respiratory Disorders

        4. 5.1.2.4 Hepatitis B and C

        5. 5.1.2.5 Autoimmune Hepatitis

        6. 5.1.2.6 Neurological Disorders

        7. 5.1.2.7 Other Therapeutics

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East & Africa

      5. 5.2.5 South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Alnylam Pharmaceuticals

      2. 6.1.2 Arcturus Therapeutics

      3. 6.1.3 Arrowhead

      4. 6.1.4 Dicerna Pharmaceuticals

      5. 6.1.5 Quark Pharmaceuticals Inc.

      6. 6.1.6 Ionis Pharmaceuticals Inc.

      7. 6.1.7 Merck & Co. Inc. (Sigma Aldrich)

      8. 6.1.8 Silence Therapeutics PLC

      9. 6.1.9 Qiagen NV

      10. 6.1.10 Phio Pharmaceuticals Corp.

      11. 6.1.11 Thermo Fisher Scientific Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The RNA-interference (RNAi) Market market is studied from 2018 - 2026.

The RNA-interference (RNAi) Market is growing at a CAGR of 10.12% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • Alnylam Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Quark Pharmaceuticals Inc.
  • Silence Therapeutics PLC
  • Arrowhead Pharmaceuticals, Inc.

Are the major companies operating in RNA-interference (RNAi) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!